S Bookstein Peretz1,2, N Regev1, L Novick1, M Nachshol1, E Goffer3, A Ben-David1,2, K Asraf4, R Doolman4, E Sapir, G Regev Yochay2,5, Y Yinon1,2. 1. Department of Obstetrics and Gynecology, Sheba Medical Center, Tel -Hashomer, Israel. 2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3. Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 4. Automated Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Israel. 5. Infection Prevention & Control Unit, Sheba Medical Center, Tel-Hashomer, Israel.
Abstract
OBJECTIVE: To determine the immunogenicity and reactogenicity of Pfizer's BNT162b2 COVID-19 vaccine among pregnant women compared with non-pregnant women, and to evaluate the obstetric outcome following vaccination. METHODS: An observational case-control study of pregnant women, who were vaccinated by a 2-dose regimen of BNT162b2 vaccine during gestation between January-February 2021 (study group) and were compared to age-matched non-pregnant women who received the vaccine during the same time period (control group). Participants received a digital questionnaire 1-4 weeks after the second dose and were asked to provide information regarding demographics, medications, medical history, history of prior SARS-CoV-2 infection, timing of COVID-19 vaccine doses, and side effects after each vaccine dose. A second digital questionnaire, regarding current pregnancy and delivery outcomes was sent to patients of the study group after the calculated due date. All recruited patients were offered a serology blood test for SARS-CoV-2 IgG following the second vaccination dose, and SARS CoV-2 IgG levels were compared between the two groups. RESULTS: Of 539 pregnant women who were recruited after completion of the 2-dose regimen of the vaccine, 390 returned the digital questionnaire and were included in the study group and compared to 260 age-matched non-pregnant women. The rate of most of the adverse events among pregnant women following vaccination was comparable to non-pregnant women except for myalgia, arthralgia and headache which were significantly less common among pregnant women after each dose and paresthesia, which was more common among the pregnant population after the second dose. There were no significant differences in the rates of side effects when receiving the vaccine at the first, second or third trimester of pregnancy. The rate of obstetrical complications, including uterine contractions (1.3% after the first dose and 6.4% after the second dose), vaginal bleeding (0.2% after the first dose and 1.5% after the second dose), and premature rupture of membranes (0% after the first dose and 0.7% after the second dose) were extremely low following vaccination. All maternal sera samples of both groups were positive for SARS CoV-2 IgG. However, pregnant women had significantly lower serum SARS CoV-2 IgG levels compared to non-pregnant women (27.03 vs 34.5 respectively, p<0.001). Among 57 women, who delivered during the study period median gestational age at delivery was 39.5 (IQR 38.7-40.0) weeks with no preterm birth <37 weeks and no cases of fetal or neonatal complications or death. CONCLUSIONS: As shown by the adverse effect profile and short-term obstetric and neonatal outcomes, no safety signals appeared among pregnant women who were vaccinated by BNT162b2vaccine at all stages of pregnancy. The vaccine is effective in generating humoral immune response in pregnant women, although IgG levels were lower than observed in non-pregnant women. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
OBJECTIVE: To determine the immunogenicity and reactogenicity of Pfizer's BNT162b2 COVID-19 vaccine among pregnant women compared with non-pregnant women, and to evaluate the obstetric outcome following vaccination. METHODS: An observational case-control study of pregnant women, who were vaccinated by a 2-dose regimen of BNT162b2 vaccine during gestation between January-February 2021 (study group) and were compared to age-matched non-pregnant women who received the vaccine during the same time period (control group). Participants received a digital questionnaire 1-4 weeks after the second dose and were asked to provide information regarding demographics, medications, medical history, history of prior SARS-CoV-2 infection, timing of COVID-19 vaccine doses, and side effects after each vaccine dose. A second digital questionnaire, regarding current pregnancy and delivery outcomes was sent to patients of the study group after the calculated due date. All recruited patients were offered a serology blood test for SARS-CoV-2 IgG following the second vaccination dose, and SARS CoV-2 IgG levels were compared between the two groups. RESULTS: Of 539 pregnant women who were recruited after completion of the 2-dose regimen of the vaccine, 390 returned the digital questionnaire and were included in the study group and compared to 260 age-matched non-pregnant women. The rate of most of the adverse events among pregnant women following vaccination was comparable to non-pregnant women except for myalgia, arthralgia and headache which were significantly less common among pregnant women after each dose and paresthesia, which was more common among the pregnant population after the second dose. There were no significant differences in the rates of side effects when receiving the vaccine at the first, second or third trimester of pregnancy. The rate of obstetrical complications, including uterine contractions (1.3% after the first dose and 6.4% after the second dose), vaginal bleeding (0.2% after the first dose and 1.5% after the second dose), and premature rupture of membranes (0% after the first dose and 0.7% after the second dose) were extremely low following vaccination. All maternal sera samples of both groups were positive for SARS CoV-2 IgG. However, pregnant women had significantly lower serum SARS CoV-2 IgG levels compared to non-pregnant women (27.03 vs 34.5 respectively, p<0.001). Among 57 women, who delivered during the study period median gestational age at delivery was 39.5 (IQR 38.7-40.0) weeks with no preterm birth <37 weeks and no cases of fetal or neonatal complications or death. CONCLUSIONS: As shown by the adverse effect profile and short-term obstetric and neonatal outcomes, no safety signals appeared among pregnant women who were vaccinated by BNT162b2vaccine at all stages of pregnancy. The vaccine is effective in generating humoral immune response in pregnant women, although IgG levels were lower than observed in non-pregnant women. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
Authors: Inbal Goldshtein; David M Steinberg; Jacob Kuint; Gabriel Chodick; Yaakov Segal; Shirley Shapiro Ben David; Amir Ben-Tov Journal: JAMA Pediatr Date: 2022-05-01 Impact factor: 26.796
Authors: Helena Blakeway; Smriti Prasad; Erkan Kalafat; Paul T Heath; Shamez N Ladhani; Kirsty Le Doare; Laura A Magee; Pat O'Brien; Arezou Rezvani; Peter von Dadelszen; Asma Khalil Journal: Am J Obstet Gynecol Date: 2021-08-10 Impact factor: 10.693
Authors: Bahaa Abu-Raya; Shabir A Madhi; Saad B Omer; Gayatri Amirthalingam; Michelle L Giles; Katie L Flanagan; Petra Zimmermann; Miguel O'Ryan; Marco A Safadi; Vassiliki Papaevangelou; Kirsten Maertens; Nasamon Wanlapakorn; Vicens Diaz-Brito; Eline Tommelein; Susanna Esposito Journal: Front Immunol Date: 2021-12-23 Impact factor: 7.561
Authors: Abanoub Riad; Anna Jouzová; Batuhan Üstün; Eliška Lagová; Lukáš Hruban; Petr Janků; Andrea Pokorná; Jitka Klugarová; Michal Koščík; Miloslav Klugar Journal: Int J Environ Res Public Health Date: 2021-12-19 Impact factor: 3.390